Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-12,177
Closed -$229K 1142
2025
Q4
$229K Buy
+12,177
New +$204K 0.01% 804
2023
Q4
Sell
-10,287
Closed -$72K 754
2023
Q3
$72K Buy
+10,287
New +$95K 0.01% 739
2022
Q3
Sell
-10,273
Closed -$221K 959
2022
Q2
$221K Buy
+10,273
New +$285K 0.01% 888
2022
Q1
Sell
-8,474
Closed -$385K 975
2021
Q4
$385K Buy
+8,474
New +$442K 0.02% 754
2020
Q1
Sell
-21,830
Closed -$471K 1413
2019
Q4
$471K Buy
+21,830
New +$501K 0.01% 1255
2019
Q2
Sell
-9,201
Closed -$290K 1140
2019
Q1
$290K Buy
+9,201
New +$268K 0.01% 812

Other funds holding CDNA

Winton Group's CDNA Position: Q1 2026 in Review

Winton Group sold out of CareDx (CDNA) in Q1 2026, closing a stake of 12,177 shares — an estimated $229K sold.

Winton Group first reported a position in CDNA in Q1 2019 and held it in 6 quarters. The position peaked at $471K in Q4 2019. 191 funds tracked by Wall St. Rank hold CDNA as of Q1 2026.

  • Winton Group reported no remaining CareDx position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 12,177 CareDx shares in Q1 2026, an estimated $229K.
  • Winton Group first reported a position in CareDx in Q1 2019 and held it in 6 quarters.
  • Winton Group's CareDx position peaked at $471K in Q4 2019.
  • 191 funds tracked by Wall St. Rank held CareDx as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.